Protagonist Therapeutics announced presentations of clinical data for icotrokinra in plaque psoriasis at the EADV 2025 Congress. Data from the Phase 3 ICONIC-ADVANCE studies demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib.
The presentations also highlighted that icotrokinra showed similar adverse event rates to placebo, indicating a favorable safety profile alongside its strong efficacy. These results further solidify icotrokinra's competitive position in the psoriasis treatment landscape.
Additionally, preclinical data for PN-881, an oral peptide IL-17 antagonist, was presented at the same congress. This showcases Protagonist's ongoing efforts to advance both its late-stage and early-stage pipeline assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.